Famciclovir Dosing for HSV and Herpes Zoster Infections
For HSV infections, use famciclovir 500 mg orally twice daily for mucocutaneous disease in adults and adolescents; for herpes zoster, use 500 mg orally every 8 hours for 7 days. These are the FDA-approved dosing regimens with established efficacy and safety profiles 1.
HSV Infection Dosing
Recurrent Genital Herpes (Episodic Treatment)
- Standard regimen: 1000 mg orally twice daily for 1 day 1
- Initiate at first sign of prodrome (tingling, itching, burning, pain) or lesion appearance
- Alternative for episodic treatment: 125 mg twice daily for 5 days 2
Recurrent Genital Herpes (Suppressive Therapy)
- Standard regimen: 250 mg orally twice daily 1
- Reduces recurrence frequency by ≥75% in patients with frequent recurrences (≥6 episodes/year) 2
- Safety and efficacy documented for 1 year of continuous use 2
Recurrent Herpes Labialis (Cold Sores)
- Single-dose regimen: 1500 mg orally as a single dose 1
- Initiate at first sign or symptom (tingling, itching, burning, pain, or lesion)
HIV-Infected Patients (Orolabial or Genital HSV)
- Standard regimen: 500 mg orally twice daily for 7 days 1
- Initiate within 48 hours of symptom onset
- This higher dose and longer duration is necessary for immunocompromised patients 3
Important caveat: The guidelines note that famciclovir is approved for adults and adolescents with mucocutaneous HSV at 500 mg twice daily, but no pediatric preparation exists and dosing data in children are limited 4. While pediatric pharmacokinetic studies have been conducted 5, famciclovir remains primarily an adult medication for HSV.
Herpes Zoster (Shingles) Dosing
Immunocompetent Adults
- Standard regimen: 500 mg orally every 8 hours (three times daily) for 7 days 1
- Initiate as soon as herpes zoster is diagnosed, ideally within 72 hours of rash onset
- Efficacy beyond 72 hours after rash onset has not been established 1
Key evidence: Famciclovir 500 mg three times daily accelerates lesion healing, reduces viral shedding duration, and most importantly, reduces postherpetic neuralgia duration by approximately 2 months compared to placebo 6. The 750 mg three times daily dose showed similar efficacy 6, but the 500 mg dose is the FDA-approved standard 1.
Alternative dosing schedules (750 mg once daily or 500 mg twice daily) have shown comparable efficacy for cutaneous healing in research settings 7, but the FDA-approved regimen remains 500 mg every 8 hours.
Renal Dose Adjustments
Critical consideration: Acute renal failure has been reported with inappropriately high doses in patients with underlying renal disease 1. Dose reduction is mandatory based on creatinine clearance:
For Herpes Zoster (Multiple-Day Dosing)
- CrCl ≥60 mL/min: 500 mg every 8 hours
- CrCl 40-59 mL/min: 500 mg every 12 hours
- CrCl 20-39 mL/min: 500 mg every 24 hours
- CrCl <20 mL/min: 250 mg every 24 hours
- Hemodialysis: 250 mg following each dialysis 1
For Recurrent Genital Herpes (1-Day Treatment)
- CrCl ≥60 mL/min: 1000 mg twice daily for 1 day
- CrCl 40-59 mL/min: 500 mg twice daily for 1 day
- CrCl 20-39 mL/min: 500 mg single dose
- CrCl <20 mL/min: 250 mg single dose
- Hemodialysis: 250 mg single dose following dialysis 1
For Suppressive Therapy
- CrCl ≥40 mL/min: 250 mg every 12 hours
- CrCl 20-39 mL/min: 125 mg every 12 hours
- CrCl <20 mL/min: 125 mg every 24 hours
- Hemodialysis: 125 mg following each dialysis 1
Comparative Context
While acyclovir remains the most extensively studied antiviral for HSV and VZV infections 4, famciclovir offers comparable efficacy with less frequent dosing 2. The intracellular half-life of penciclovir triphosphate (the active metabolite) is considerably longer than acyclovir triphosphate (7 hours vs. 1 hour in VZV-infected cells) 7, which explains the less frequent dosing advantage.
Common pitfall: Do not use famciclovir for first-episode genital herpes, ophthalmic zoster, or in immunocompromised patients other than HIV-infected individuals with recurrent orolabial or genital herpes—efficacy and safety have not been established in these populations 1.